The World Health Organization has prequalified Coartem Baby, the first and only antimalarial for babies. Novartis developed this combination drug in partnership with Medicines for Malaria Venture.

The post Novartis Antimalarial Clears Key WHO Review to Get the Combo Drug to Babies appeared first on MedCity News.

GSK’s bepirovirsen met the main goal of two Phase 3 studies, achieving functional cure rates for patients with chronic hepatitis B infection after six months of treatment. This antisense oligonucleotide therapy could provide a treatment alternative to antiviral drugs that patients must take for life.

The post GSK Gets Closer to Bringing Patients a Functional Cure for Chronic Hepatitis B appeared first on MedCity News.

A report supporting the CDC’s revisions says the U.S. is an outlier in the number of diseases and the total number of vaccine doses recommended in its pediatric vaccine schedule. But some physician groups say comparisons to other countries can be misguided and removing vaccines from the schedule puts children’s health at risk.

The post CDC Removal of Six Diseases From Child Vaccination Schedule Sparks Concern From Clinicians appeared first on MedCity News.

Merck’s Cidara Therapeutics acquisition brings a lead program with potential to become a first-in-class drug for preventing influenza infection. A Phase 3 study is already underway, timed to coincide with the start of the flu season in the Northern Hemisphere.

The post Merck Makes Big Antiviral Move With $9B Deal to Land Cidara’s Late-Stage Drug for Flu Prevention appeared first on MedCity News.

Phase 3 results for the Novartis malaria drug “GanLum” show it was comparable to the standard of care and led to cure rates that top the threshold recommended by the World Health Organization. If approved, this new combination drug would become the first novel malaria therapy in more than 25 years.

The post Novel Novartis Malaria Drug Shows Promise to Become New Asset Against Resistant Strains appeared first on MedCity News.

The six new drugs awarded FDA Commissioner’s National Priority Vouchers brings to 15 the total number of therapies selected for the new pilot program. Under this program, the FDA says the standard 10- to 12-month review time could be shaved down to “within months.”

The post FDA Adds 6 More Meds to Pilot Program for Speedy Review of Drugs in the National Interest appeared first on MedCity News.

By making RT-PCR testing a routine option in outpatient and urgent care settings — and by educating all stakeholders along the clinical continuum — we can significantly reduce unnecessary antibiotic use, protect the effective drugs we still have, and ensure that bacterial infections remain treatable for future generations.

The post From Urgent Care to Smarter Care: Using Rapid Testing to Fight Antibiotic Resistance appeared first on MedCity News.

Novartis malaria drug Coartem has expanded its approval to include babies. The combination drug, originally formulated as a tablet, has a new dose strength and formulation designed for treating newborns and young infants who develop malarial infections.

The post Novartis Drug Becomes First Malaria Therapy for Newborns and Infants appeared first on MedCity News.

Infectious disease is the focus of the biopharma track at INVEST Pitch Perfect May 20-21 in Chicago. Register today!

The post A Snapshot of Five Contenders to Combat Infectious Diseases in the Post-Pandemic Landscape appeared first on MedCity News.

The deadline to apply for the INVEST Pitch Perfect Contest is January 24! In addition to a business profile, Pitch Perfect winners also receive a $20,000 branding advertising package from MedCity News.

The post Healthcare Startups are Running Out of Time appeared first on MedCity News.

Radiant Biotherapeutics’ Multabodies are antibodies engineered to offer better binding strength to their targets. The preclinical startup’s lead program goes after a cancer immunotherapy target being pursued by several biotech companies already in early clinical development.

The post Gates Foundation Joins Radiant Bio’s $35M Round for Antibody Drugs With ‘Better Grip’ appeared first on MedCity News.

Emergent BioSolutions’ smallpox vaccine, ACAM2000, now has an additional FDA approval covering mpox. It’s one of two FDA-approved mpox vaccines, joining Jynneos from Bavarian Nordic.

The post FDA Approves Emergent BioSolutions Vaccine as New Tool in Fight Against Mpox appeared first on MedCity News.

GSK is taking over development of an avian influenza vaccine candidate as a bird flu outbreak continues in U.S. dairy cows. Meanwhile, CureVac is restructuring and returning its attention to cancer vaccines, which was the initial focus of the mRNA company.

The post GSK Pays CureVac €400M to Pick Up Clinical-Stage mRNA Vaccines for Infectious Diseases appeared first on MedCity News.

Bavarian Nordic will concentrate on its portfolio and pipeline of infectious diseases vaccines, including top seller Jynneos, approved for mpox and smallpox. The company only had one clinical-stage cancer vaccine program.

The post Bavarian Nordic Hones Infectious Disease Focus by Dropping Cancer Vaccine R&D appeared first on MedCity News.

Marburg virus has no FDA-approved vaccines or therapies, but a vaccine candidate from the National Institutes of Health now has encouraging results from a U.S. clinical trial. Next steps include tests in more countries including Ghana, where a Marburg outbreak was declared last summer.

The post NIH Marburg Vaccine Posts Encouraging Results in First-in-Human Study appeared first on MedCity News.

Respiratory syncytial virus has no approved vaccines anywhere in the world, but the chase to bring the first one to the market is heating up. GSK reported Phase 3 data that position it for regulatory submissions the pharma giant is planning for later this year. Pfizer is also on track to seek regulatory approvals for its RSV vaccine candidate.

The post GSK’s Phase 3 results make it a top contender in chase for first RSV vaccine appeared first on MedCity News.

Shares of the company were up more than 13 percent on the Tel Aviv Stock Exchange following the approval of Talicia, meant to address the growing issue of the bacteria’s resistance to antibiotics. H. pylori is a major cause of gastric cancer.

The post FDA approves RedHill’s drug for cancer-causing H. pylori bacterial infections appeared first on MedCity News.

Harvard’s Wyss Institute and VC firm Miraki Innovation have created a joint venture BOA Biomedical, which is developing a device that could diagnose and treat infectious diseases.

The post BOA Biomedical seeks to address antibiotic resistance and sepsis appeared first on MedCity News.

The company, which is called Infectious Disease (ID) Connect, aims to virtually connect UPMC infectious disease specialists to other hospitals.

The post UPMC creates telemedicine company to address shortage of infectious disease specialists appeared first on MedCity News.

The study, conducted with St. Jude Children’s Research Hospital, showed a 78 percent predictive sensitivity two days before the onset of infection.

The post Karius’ NGS test for infections shows high sensitivity in pilot study appeared first on MedCity News.

The ultimate goal of MeMed is to right-size antibiotic use. The team is working on a second-generation platform that gets results in minutes and that anyone can use.

The post MeMed gets $9.2M to develop tools to distinguish between bacterial and viral infections appeared first on MedCity News.

The post Sherwin-Williams debuts Paint Shield to prevent spread of bacteria on surfaces appeared first on MedCity News.

The post ‘Microbial cloud’ in breath could identify you, much like skin or hair appeared first on MedCity News.

The post Treatment of Infectious Diseases Takes a Step Back in the 21st Century appeared first on MedCity News.

The post Toby Cosgrove: Never mind Ebola and start worrying about the flu appeared first on MedCity News.

The post How dangerous IS that infectious disease? This infograph tells you appeared first on MedCity News.